Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 5;2(2):CD008342.
doi: 10.1002/14651858.CD008342.pub2.

Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates

Stephanie Ardell  1 , Martin Offringa, Colleen Ovelman, Roger Soll
Affiliations

Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates

Stephanie Ardell et al. Cochrane Database Syst Rev. .

Abstract

Background: Vitamin K is necessary for the synthesis of coagulation factors. Term infants, especially those who are exclusively breast fed, are deficient in vitamin K and consequently may have vitamin K deficiency bleeding (VKDB). Preterm infants are potentially at greater risk for VKDB because of delayed feeding and subsequent delay in the colonization of their gastrointestinal system with vitamin K producing microflora, as well as immature hepatic and hemostatic function. OBJECTIVES: To determine the effect of vitamin K prophylaxis in the prevention of vitamin K deficiency bleeding (VKDB) in preterm infants.

Search methods: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 11), MEDLINE via PubMed (1966 to 5 December 2016), Embase (1980 to 5 December 2016), and CINAHL (1982 to 5 December 2016). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles.

Selection criteria: Randomized controlled trials (RCTs) or quasi-RCTs of any preparation of vitamin K given to preterm infants.

Data collection and analysis: We evaluated potential studies and extracted data in accordance with the recommendations of Cochrane Neonatal.

Main results: We did not identify any eligible studies that compared vitamin K to no treatment.One study compared intravenous (IV) to intramuscular (IM) administration of vitamin K and compared various dosages of vitamin K. Three different prophylactic regimes of vitamin K (0.5 mg IM, 0.2 mg vitamin K1, or 0.2 mg IV) were given to infants less than 32 weeks' gestation. Given that only one small study met the inclusion criteria, we assessed the quality of the evidence for the outcomes evaluated as low.Intramuscular versus intravenousThere was no statistically significant difference in vitamin K levels in the 0.2 mg IV group when compared to the infants that received either 0.2 or 0.5 mg vitamin K IM (control) on day 5. By day 25, vitamin K1 levels had declined in all of the groups, but infants who received 0.5 mg vitamin K IM had higher levels of vitamin K1 than either the 0.2 mg IV group or the 0.2 mg IM group.Vitamin K1 2,3-epoxide (vitamin K1O) levels in the infants that received 0.2 mg IV were not statistically different from those in the control group on day 5 or 25 of the study. All of the infants had normal or supraphysiologic levels of vitamin K1 concentrations and either no detectable or insignificant amounts of prothrombin induced by vitamin K absence-II (PIVKA II).Dosage comparisonsDay 5 vitamin K1 levels and vitamin K1O levels were significantly lower in the 0.2 mg IM group when compared to the 0.5 mg IM group. On day 25, vitamin K1O levels and vitamin K1 levels in the 0.2 mg IM group and the 0.5 mg IM group were not significantly different. Presence of PIVKA II proteins in the 0.2 mg IM group versus the 0.5 mg IM group was not significantly different at day 5 or 25 of the study.

Authors' conclusions: Preterm infants have low levels of vitamin K and develop detectable PIVKA proteins during the first week of life. Despite being at risk for VKDB, there are no studies comparing vitamin K versus non-treatment and few studies that address potential dosing strategies for effective treatment. Dosage studies suggest that we are currently giving doses of vitamin K to preterm infants that lead to supraphysiologic levels. Because of current uncertainty, clinicians will have to extrapolate data from term infants to preterm infants. Since there is no available evidence that vitamin K is harmful or ineffective and since vitamin K is an inexpensive drug, it seems prudent to follow the recommendations of expert bodies and give vitamin K to preterm infants. However, further research on appropriate dose and route of administration is warranted.

PubMed Disclaimer

Conflict of interest statement

SA has no conflict to declare. RS has no conflict to declare. CO has no conflict to declare. MO has no conflict to declare.

Figures

1
1
PRISMA flow diagram
2
2
Forest plot of comparison: 1 Intravenous versus intramuscular vitamin K, outcome: 1.3 Presence of PIVKA II at day 5.
3
3
Forest plot of comparison: 2 Vitamin K dosage, outcome: 2.3 Presence of PIVKA II at day 5.
1.1
1.1. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 1 Bleeding complications.
1.2
1.2. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 2 Intraventricular hemorrhage > Grade II.
1.3
1.3. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 3 Presence of PIVKA II at day 5.
1.4
1.4. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 4 Presence of PIVKA II at day 25.
1.5
1.5. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 5 Prolonged PT at day 5.
1.6
1.6. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 6 Vitamin K1 epoxide detected (≥ 10 ng/mL on day 5).
1.7
1.7. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 7 Vitamin K1 epoxide detected (≥ 0.3 ng/mL on day 25).
1.8
1.8. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 8 Necrotizing enterocolitis.
1.9
1.9. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 9 Sepsis.
1.10
1.10. Analysis
Comparison 1 Intravenous versus intramuscular vitamin K, Outcome 10 Mortality (all infants).
2.1
2.1. Analysis
Comparison 2 Vitamin K dosage, Outcome 1 Bleeding complications.
2.2
2.2. Analysis
Comparison 2 Vitamin K dosage, Outcome 2 Intraventricular hemorrhage > Grade II.
2.3
2.3. Analysis
Comparison 2 Vitamin K dosage, Outcome 3 Presence of PIVKA II at day 5.
2.4
2.4. Analysis
Comparison 2 Vitamin K dosage, Outcome 4 Presence of PIVKA II at day 25.
2.5
2.5. Analysis
Comparison 2 Vitamin K dosage, Outcome 5 Prolonged PT at day 5.
2.6
2.6. Analysis
Comparison 2 Vitamin K dosage, Outcome 6 Vitamin K1 epoxide detected (≥ 10 ng/mL on day 5).
2.7
2.7. Analysis
Comparison 2 Vitamin K dosage, Outcome 7 Vitamin K1 epoxide detected (≥ 0.3 ng/mL on day 25).
2.8
2.8. Analysis
Comparison 2 Vitamin K dosage, Outcome 8 Necrotizing enterocolitis.
2.9
2.9. Analysis
Comparison 2 Vitamin K dosage, Outcome 9 Sepsis.
2.10
2.10. Analysis
Comparison 2 Vitamin K dosage, Outcome 10 Mortality (all infants).
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008342

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Clarke 2006 {published data only}
    1. Clarke P, Mitchell SJ, Shearer MJ. Total and differential phylloquinone (Vitamin K1) intakes of preterm infants from all sources during the neonatal period. Nutrients 2015;7(10):8308‐20. [DOI: 10.3390/nu7105393; PUBMED: 26426042] - DOI - PMC - PubMed
    1. Clarke P, Mitchell SJ, Sundaram S, Win T, Roeves D, Shearer MJ. Vitamin K prophylaxis in preterm infants: evidence for current dose recommendations. Pediatric Academic Societies Annual Meeting; 2005 May 14‐17; Washington DC. Washington DC: Pediatric Academic Societies, 2005; Vol. 57:1321.
    1. Clarke P, Mitchell SJ, Wynn R, Sundaram S, Sharma V, Gardener E, et al. Vitamin K status in preterm Infants: a randomised controlled trial to compare three regimes of prophylaxis. Pediatric Academic Society Abstract Archive 2002‐2015. 2004; Vol. 2520.
    1. Clarke P, Mitchell SJ, Wynn R, Sundaram S, Sharma V, Gardener E, et al. Vitamin K status in preterm infants: a randomised controlled trial to compare three regimes of prophylaxis. Eastern Society for Pediatric Research Abstracts. 2004; Vol. 54:473.
    1. Clarke P, Mitchell SJ, Wynn R, Sundaram S, Speed V, Gardener E, et al. Vitamin K prophylaxis for preterm infants: a randomized, controlled trial of 3 regimens. Pediatrics 2006;118(6):e1657‐66. - PubMed

References to studies excluded from this review

Costakos 2003 {published data only}
    1. Costakos DT, Greer FR, Love LA, Dahlen LR, Suttie JW. Vitamin K prophylaxis for premature infants: 1 mg versus 0.5 mg. American Journal of Perinatology 2003;20(8):485‐90. - PubMed
Kumar 2001 {published data only}
    1. Kumar D, Greer FR, Super DM, Suttie JW, Moore JJ. Vitamin K status of premature infants: implications for current recommendations. Pediatrics 2001;108(5):1117‐22. [PUBMED: 11694690] - PubMed
Ogata 1988 {published data only}
    1. Ogata T, Motohara K, Endo F, Kondo Y, Ikeda T, Kudo Y, et al. Vitamin K effect in low birth weight infants. Pediatrics 1988;81(3):423‐7. [PUBMED: 3344186] - PubMed
Rossi 1996 {published data only}
    1. Rossi R, Albrecht O, Pollmann H, Jorch G, Harms E. Effect of a reduced vitamin K supplementation on prothrombin time in prematures and high‐risk neonates. Acta Paediatrica 1996;85(6):747‐9. - PubMed
Seydewitz 1984 {published data only}
    1. Seydewitz HH, Witt I, Pringsheim W, Kunzer W. The influence of vitamin K administration on the levels of prothrombin and acarboxy‐prothrombin in premature and small‐for‐date newborns during the first day of life; 3rd Congress on Thrombosis and Hemostasis, 1984 February 15‐18; Berne. Blut 1984;49(2):137‐8.
Vakrilova 1995 {published data only}
    1. Vakrilova L, Slŭncheva B, Mladenova A. The effects of intramuscular and oral prophylaxis with vitamin K on the coagulation status of low‐weight newborn infants [Bulgarian]. Akusherstvo i Ginekologiia (Sofiia) 1995;34(1):12‐4. - PubMed

Additional references

Andrew 1988
    1. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72(5):1651‐7. - PubMed
Bovill 1993
    1. Bovill EG, Soll RF, Lynch M, Bhushan F, Landesman M, Freije M, et al. Vitamin K1 metabolism and the production of des‐carboxy prothrombin and protein C in the term and premature neonate. Blood 1993;81(1):77‐83. - PubMed
Clarke 2003
    1. Clarke P, Mitchell S. Vitamin K prophylaxis in preterm infants: current practices. Journal of Thrombosis and Haemostasis 2003;1(2):384‐6. - PubMed
Clarke 2005
    1. Clarke P, Mitchell SJ, Sundaram S, Sharma V, Wynn R, Shearer M. Vitamin K status of preterm infants with a prolonged prothrombin time. Acta Paediatrica 2005;94(12):1822‐4. - PubMed
Clarke 2010
    1. Clarke P. Vitamin K prophylaxis for preterm infants. Early Human Development 2010;86(Supplement 1):17‐20. - PubMed
Committee on Fetus and Newborn 2003
    1. American Academy of Pediatrics Committee on Fetus and Newborn. Controversies concerning vitamin K and the newborn. Pediatrics 2003;112(1 Pt 1):191‐2. - PubMed
Crowther 2010
    1. Crowther CA, Crosby DD, Henderson‐Smart DJ. Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD000229.pub2] - DOI - PMC - PubMed
Dickson 1994
    1. Dickson RC, Stubbs TM, Lazarchick J. Antenatal vitamin K therapy in the low‐birth‐weight infant. American Journal of Obstetrics and Gynecology 1994;170(1 Pt 1):85‐90. - PubMed
GRADEpro GDT 2015 [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 5 December 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Greer 1998
    1. Greer FR, Marshall SP, Severson RR, Smith DA, Shearer MJ, Pace DG, et al. A new mixed micellar preparation for oral vitamin K prophylaxis: randomized controlled comparison with an intramuscular formulation in breast fed infants. Archives of Disease in Childhood 1998;79(4):300‐5. - PMC - PubMed
Greer 2010
    1. Greer FR. Vitamin K the basics ‐ what's new?. Early Human Development 2010;86(Suppl 1):43‐7. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kurata 2005
    1. Kurata M, IIdaka T, Yamasaki N, Sasyama Y, Hamada Y. Battery of tests profiling abnormalities of Vitamin K‐dependent coagulation factors in drug‐toxicity studies in rats. Experimental Animals 2005;54(2):189‐92. - PubMed
Liu 2006
    1. Liu J, Wang Q, Zhao JH, Chen YH, Qin GL. The combined antenatal corticosteroids and vitamin K therapy to prevent periventricular‐intraventricular hemorrhage in premature newborns less than 35 weeks gestational age. Journal of Tropical Pediatrics 2006;52(5):355‐9. - PubMed
Morales 1988
    1. Morales WJ, Angel JL, O'Brien WF, Knuppel RA, Marsalisi F. The use of antenatal vitamin K in the prevention of early neonatal intraventricular hemorrhage. American Journal of Obstetrics and Gynecology 1988;159(3):774‐9. - PubMed
O'Shaughnessy 2005
    1. O’Shaughnessy D, Allen C, Woodcock T, Pearce K, Harvey J, Shearer M. Echis time, under‐carboxylated prothrombin and vitamin K status in intensive care patients. Clinical and Laboratory Haematology 2003;25(6):397‐404. - PubMed
Offringa 2000
    1. Puckett RM, Offringa M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002776] - DOI - PMC - PubMed
Pilcher 2008
    1. Pilcher E, Pilcher L. The neonatal coagulation system and the vitamin K deficiency bleeding ‐ a mini review. Wiener Medizinische Wochenschrift 2008;158(13‐4):385‐95. - PubMed
Pomerance 1987
    1. Pomerance JJ, Teal JG, Gogolok JF, Brown S, Stewart ME. Maternally administered antenatal vitamin K1: effect on neonatal prothrombin activity, partial thromboplastin time, and intraventricular hemorrhage. Obstetrics and Gynecology 1987;70(2):235‐41. - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. Available from https://gdt.gradepro.org/app/handbook/handbook.html. (accessed 01 September 2017).
Solano 1990
    1. Solano C, Cobcroft RG, Scott DC. Prediction of vitamin K response using the Echis time and Echis‐prothrombin time ratio. Thrombosis and Haemostasis 1990;64(3):353‐7. - PubMed
Van Winckel 2009
    1. Winckel M, Bruyne R, Velde S, Bierveliet S. Vitamin K, an update for the pediatrician. European Journal of Pediatrics 2009;168(2):127‐34. - PubMed
Yang 1989
    1. Yang YM, Simon N, Maertens P, Brigham S, Liu P. Maternal‐fetal transport of Vitamin K1 and its effects on coagulation in premature infants. Journal of Pediatrics 1989;115(6):1009‐13. - PubMed
Zipursky 1999
    1. Zipursky A. Prevention of vitamin K deficiency in newborns. British Journal of Haematology 1999;106(1):256. - PubMed

References to other published versions of this review

Ardell 2010
    1. Ardell S, Offringa M, Soll R. Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008342] - DOI - PMC - PubMed

Publication types

LinkOut - more resources